Venky Soundararajan is the Founder & Chief Scientific Officer of nference where he leads the development and translation of the nferX Artificial Intelligence (AI) technology platform. He is also the Founding CSO of the biotechnology company Qrativ, which was established as a Joint Venture between the Mayo Clinic and nference. Previously, he led translational oncology modeling and simulation efforts at Vertex Pharmaceuticals, and designed new genetic engineering tools with synthetic biology pioneer George Church at Harvard Medical School. Venky also developed a novel platform for network theory based in-silico Antibody Engineering at MIT, culminating in a pair of Clinical-stage broad-spectrum antibodies against Influenza (Flu) and Dengue viruses. At the Koch Institute for Integrative Cancer Research at MIT, he led a team of scientists that uncovered fundamental evolutionary constraints of hypermutative zoonotic infectious pathogens (INFV, DENV, WNV, HIV, HCV, EBV, HPV). These cumulative scientific and translational efforts have led to the advancement of immunotherapy agents for stemming both viral evolution and tumor growth.
Venky has authored 40+ patent applications, granted patents, book chapters, and peer-reviewed papers in Nature Biotechnology, Nature Communications etc. He received his Ph.D. degree in Biological Engineering from MIT, and B.Tech. degree in Electronics & Communication Engineering from the Indian Institute of Technology (IIT).